IPO Do Overs Are Do...
Health Care: Drugs
Rexahn Pharmaceuticals Inc. (RNN: AMEX)
$0.60 -0.02 | -3.23%
02/09/12 - 03:49 PM ET
34.99K / 349.90K
Vol / Avg. Vol:0.62 / 0.62
Open / Prev. Close:0.60 - 0.62
Today's Range:0.34 - 1.83
52 Wk Range:64.89%
Performance YTD:TheStreet Rating:
Portfolios with RNN
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- Userinsider buying
- Contributor6 Stocks With Big Insider B...
- Contributor6 Penny Stocks for the Biot...
- Userdec28/10
- Userw0wieet Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- User©SUPRATRADE HOT STOCKS (...
- Usergeorge paizakis
- UserBesV Portfolio 1
Latest RNN Headlines from TheStreet
- Insiders Trading FURX, MELI, FRP 05.23.11 | 08:05 am
- 6 Stocks With Big Insider Buying 04.12.11 | 02:04 pm
- Insiders Trading RNN, LULU, KYN, GES 04.06.11 | 09:04 am
- Biotech Mailbag: BIO CEO Wrap 02.18.11 | 07:02 am
- Biotech Stock Mailbag: Protalix BioTherapeutics 02.11.11 | 07:02 am
- Rexahn Higher on Deja Vu Stock Promotion 02.08.11 | 08:02 am
- 6 Penny Stocks for the Biotech Boom 02.01.11 | 03:02 pm
- Genoptix, Clinical Data: Small-Cap Winners 01.24.11 | 01:01 pm
- Wendy's/Arby's, BioLase: Small-Cap Winners 01.20.11 | 12:01 pm
- Stocks Under $5 Least Likely to Go Bankrupt 09.16.10 | 06:09 am
Press Releases for RNN
- Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds - Business Wire 01.25.12 | 08:01 am
- Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors - Business Wire 01.18.12 | 08:01 am
- Rexahn Pharmaceuticals Provides Key Goals For 2012 - Business Wire 01.17.12 | 08:01 am
- Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin® As Treatment For Major Depressive Disorder - Business Wire 11.04.11 | 08:11 am
- Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds - Business Wire 10.12.11 | 08:10 am
- Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin® - Business Wire 10.03.11 | 08:10 am
- Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer - Business Wire 09.28.11 | 08:09 am
- Rexahn Pharmaceuticals To Present At The Rodman & Renshaw 13th Annual Healthcare Conference - Business Wire 09.08.11 | 08:09 am
- Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction - Business Wire 09.06.11 | 08:09 am
- European Patent Granted For Neurotherapeutic Compositions - Business Wire 08.08.11 | 08:08 am
Partner Headlines for RNN
- Inhibitex: This Is One You Might Want To Grow With - Seeking Alpha 11.09.11 | 09:11 am
- Rexahn Is a Bargain Buy - Seeking Alpha 05.31.11 | 08:05 am
- Rexahn Pharma Reports Two-Thirds of Patients Enrolled in Key Clinical Trial - Seeking Alpha 05.06.11 | 09:05 am
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
- 5 Healthcare Stocks That Insiders Are Buying Now - Seeking Alpha 04.12.11 | 08:04 am
- Rexahn to Raise $10M in Registered Direct Offering - Benzinga 03.28.11 | 01:03 pm
- Trading Halted: Rexahn Pharmaceuticals, News Pending - Benzinga 03.28.11 | 01:03 pm
- Rexahn Should Run Again - SeekingAlpha.com 04.20.10 | 04:04 pm
- Rexahn Pharma Presents a Landmark in Clinical Trial Data Interpretation - SeekingAlpha.com 04.18.10 | 10:04 am
- Trading Updates for Rexahn, Neostem and Radient - SeekingAlpha.com 04.15.10 | 04:04 pm
